DSM PTG, part of DSM Biomedical, a global leader in biomedical materials science, today announced the availability of Bionate® II PCU, a versatile medical polymer with built-in surface technology designed for chronic implants.
Bionate® II PCU is a line extension of the well known Bionate® Polycarbonate Urethane family, one of the industry’s leading medical polymers for long-term implants and is backed by an established FDA Master File. The new polymer offers improved performance and processing characteristics for medical devices. It includes patented SAME® technology, a built-in surface modification utilizing surface activity and self assembly of chemical groups attached to the ends of each polymer molecule during synthesis. This breakthrough technology enables medical devices to be equipped with permanent surface modification while maintaining excellent mechanical properties. It can also eliminate the need for secondary surface treatments once a device is made.
Cincinnati-based PMC Medical, a contract manufacturer delivering solutions in complex polymer molding and assembly, evaluated the processability of Bionate® PCU versus Bionate® II PCU. "Upon the conclusion of our experiments, we determined that DSM PTG's Bionate® II PCU is more easily processed for injection molding applications," said Bob Langlois, Executive Director of Applied Technology
In addition to providing controlled surface chemistry and better processing, Bionate® II PCU also offers improved oxidative stability and greater strength than the first generation Bionate® PCU.